Recent Updates
Recently added Catalysts
BMRN

BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the...

Key Takeaway: SAN RAFAEL, Calif. , Nov. 12, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on November 21, 2019 at 1:20pm GMT / 8:20am

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
7.9%
average across 8 past catalysts
Lead asset
Valoctocogene roxaparvovec
Phase 3 · Hemophilia A

Full Press Release Details

SAN RAFAEL, Calif. , Nov. 12, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on November 21, 2019 at 1:20pm GMT / 8:20am ET . To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com . A replay will also be archived on the site for at least one week following each event.
About BioMarin BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.
Contacts:
Investors Media
Traci McCarty Debra Charlesworth
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (415) 455-7451
Last updated: Nov 12, 2019